CATL Shares Fall as Hungary Plant Faces Safety Halt 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Milei Threatens Falkland Oil Firms With Sanctions 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
OpenAI Rejects Apple Trade Secret Theft Claims 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Add as a preferred source on Google
SAN DIEGO and TORONTO, March 08, 2018 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with life-threatening hematologic cancers, will release its financial results for the quarter and year ended December 31, 2017, on Tuesday, March 27, 2018 after the close of the market.
| Conference Call & Webcast: Tuesday, March 27th @ 5:00pm Eastern Time | ||
| Toll-Free: | (844) 882-7834 | |
| International: | (574) 990-9707 | |
| Passcode: | 8873259 | |
| Webcast: | https://edge.media-server.com/m6/p/h526hjyv | |
| Replays available through April 3rd, 2018 | ||
| Toll-Free: | (855) 859 2056 | |
| Replay Passcode: | 8873259 | |
The live conference call can also be accessed through a link on the Investor Relations section of Aptose’s website at ir.aptose.com. Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. An archived version of the webcast along with a transcript will be available on the company’s website for 30 days.
The press release, the financial statements and the management’s discussion and analysis for the quarter ended and year ended December 31, 2017 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
For further information, please contact:
Aptose Biosciences
Greg Chow, CFO
647-479-9828
Email: [email protected]
SMP Communications
Susan Pietropaolo
201-923-2049
[email protected]
LifeSci Advisors
Michael Wood
Managing Director
646-597-6983
[email protected]
